January 13-16, 2025, San Francisco, CA IRVINE, Calif., December 9, 2024 – PRISM MediaWire – Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend “J.P.
IRVINE, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend “J.P.
IRVINE, Calif., Dec. 04, 2024 – PRISM MediaWire – Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, today announced the publication of favorable data regarding its DetermaCNI™ assay.
IRVINE, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, today announced the publication of favorable data regarding its DetermaCNI™ assay.
IRVINE, Calif., Dec. 02, 2024 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today announced additional favorable data regarding its lead assay VitaGraft™, which was published in the journal Nephrology Dialysis Transplantation.
IRVINE, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a diagnostics technology company, today announced additional favorable data regarding its lead assay VitaGraft™, which was published in the journal, Nephrology Dialysis Transplantation.
OncoCyte Corporation (NASDAQ:OCX ) Q3 2024 Results Conference Call November 12, 2024 5:00 PM ET Company Participants Julie Silber - PCG Advisory Josh Riggs - President and CEO Andrea James - CFO Ekke Schutz - Chief Science Officer Conference Call Participants Joseph Conway - Needham Vidyun Bais - BTIG Operator Thank you for standing by. My name is Kayla, and I will be your conference operator t...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.